['type 2 diabetes']
['dulaglutide', 'placebo']

        Inclusion Criteria:

          -  Have had type 2 diabetes (T2D) for ≥6 months according to the World Health
             Organization (WHO) classification

          -  Have HbA1c of 7.0% to 10.0%, inclusive, as assessed by the central laboratory

          -  Have been treated with stable doses of metformin for at least 3 months

          -  Have a body mass index (BMI) ≥25 kilograms per square meter

        Exclusion Criteria:

          -  Have type 1 diabetes (T1D)

          -  Have used any glucose-lowering medication other than metformin 3 months prior to study
             entry or during screening/lead-in period or have used any glucagon-like peptide-1
             receptor agonists (GLP-1 RAs) at any time in the past

          -  Have had any of the following cardiovascular conditions: acute myocardial infarction
             (MI), New York Heart Association Class III or Class IV heart failure, or
             cerebrovascular accident (stroke)

          -  Have acute or chronic hepatitis, signs and symptoms of any other liver disease other
             than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level
             >2.5 times the upper limit of the reference range, as determined by the central
             laboratory at study entry; participants with NAFLD are eligible for participation in
             this trial

          -  Have had chronic or acute pancreatitis any time prior to study entry

          -  Have an estimated glomerular filtration rate (eGFR) <45 milliliters/minute/1.73 square
             meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation

          -  Have serum calcitonin ≥20 picograms per milliliter, as determined by the central
             laboratory at study entry
      